Related Experiment Video
Updated: Jun 20, 2026

In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Only a partial shield: local vancomycin postpones but does not prevent hip and knee prosthetic infections
Alexander Darup1, Max Ettinger2, Peter Savov2
1Division of Orthopaedics at Campus Pius-Hospital, Carl von Ossietzky University Oldenburg, School of Medicine and Health Sciences, Oldenburg, Germany. Alexander.Darup@pius-hospital.de.
Insights
Intraarticular vancomycin powder did not reduce periprosthetic joint infection (PJI) rates after total joint arthroplasty. However, it was associated with a delayed onset of infection, potentially complicating diagnosis.
Area of Science:
- Orthopedic Surgery
- Infectious Disease Prevention
- Pharmacology
Background:
- Periprosthetic joint infection (PJI) is a serious complication of total hip arthroplasty (THA) and total knee arthroplasty (TKA).
- Intraarticular vancomycin powder is used perioperatively to prevent PJI, but its effectiveness is debated.
- This study evaluates vancomycin's impact on PJI incidence and wound complications.
Purpose of the Study:
- To assess if topical vancomycin powder reduces PJI rates after primary total joint arthroplasty (TJA).
- To determine if intraarticular vancomycin increases the risk of wound complications.
- To analyze the time to infection in patients receiving vancomycin.
Main Methods:
- Retrospective monocentric cohort study of primary THA and TKA procedures (2022-2023).
- Comparison of PJI rates, complications, and time to infection between vancomycin and control groups.
- Vancomycin powder was implemented as a standard perioperative protocol from January 2023.
Main Results:
- 1,499 patients included: 818 in vancomycin group (VG) and 681 in control group (CG).
- No significant difference in PJI rates (1.0% VG vs. 0.9% CG) or wound healing disorders.
- Significant delay in infection onset in VG (41.5 days) compared to CG (16.5 days).
Conclusions:
- Intraarticular vancomycin powder did not reduce overall PJI rates in primary TJA.
- Vancomycin application was associated with a longer time to infection onset.
- Findings suggest vancomycin may delay clinical manifestation rather than prevent infection, potentially complicating diagnosis and treatment.
Introduction:
Periprosthetic joint infection (PJI) represents a severe complication following total hip arthroplasty (THA) and total knee arthroplasty (TKA). The intraarticular application of vancomycin powder is increasingly integrated into perioperative standards as an innovative strategy for PJI prevention. Yet the efficacy of this method remains a topic of debate. The aim of this retrospective cohort study was to evaluate whether topical vancomycin application reduces the incidence of PJI after primary total joint arthroplasty (TJA) and whether it is associated with an increased risk of wound complications.
Materials And Methods:
In this retrospective monocentric cohort study, all primary THA and TKA procedures performed between January 1, 2022, and December 31, 2023, were analysed. From January 1, 2023, intraarticular vancomycin powder was implemented as part of the standard perioperative protocol for PJI prevention. The PJI rates, postoperative surgery-related complications, and time to infection were compared between the vancomycin and control groups.
Results:
A total of 1,499 patients were included in the study. Patients were divided into two groups: a vancomycin group (VG, n = 818) and a control group (CG, n = 681). No statistically significant group differences were observed for wound healing disorders (p = 0.775) or PJI rates (1.0% VG vs. 0.9% CG, p = 0.846). However, there was a statistically significant delay in the onset of infection in the VG compared to the CG (41.5 vs. 16.5 days, p = 0.006).
Conclusion:
Intraarticular application of vancomycin powder was not associated with a reduction in overall PJI rates after primary TJA but appeared to be associated with a longer time to infection. These findings may suggest that local vancomycin application delays the clinical manifestation of infection rather than preventing it, potentially complicating the diagnosis of PJI and limiting less invasive treatment options.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Antimicrobial Effectiveness
